The Sympathetic Nervous System in Obesity Hypertension

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2013 May 17

PMID 23677623

Citations 31

Authors

Thomas E Lohmeier

Radu Iliescu

Affiliations

Soon will be listed here.

Abstract

Abundant evidence supports a role of the sympathetic nervous system in the pathogenesis of obesity-related hypertension. However, the nature and temporal progression of mechanisms underlying this sympathetically mediated hypertension are incompletely understood. Recent technological advances allowing direct recordings of renal sympathetic nerve activity (RSNA) in conscious animals, together with direct suppression of RSNA by renal denervation and reflex-mediated global sympathetic inhibition in experimental animals and human subjects have been especially valuable in elucidating these mechanisms. These studies strongly support the concept that increased RSNA is the critical mechanism by which increased central sympathetic outflow initiates and maintains reductions in renal excretory function, causing obesity hypertension. Potential determinants of renal sympathoexcitation and the differential mechanisms mediating the effects of renal-specific versus reflex-mediated, global sympathetic inhibition on renal hemodynamics and cardiac autonomic function are discussed. These differential mechanisms may impact the efficacy of current device-based approaches for hypertension therapy.

Citing Articles

Urinary Proteome Characterization of Stroke-Prone Spontaneously Hypertensive Rats.

Meng W, Gao Y Int J Mol Sci. 2025; 26(1.

PMID: 39795879 PMC: 11720275. DOI: 10.3390/ijms26010021.

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review.

Jarade C, Zolotarova T, Moiz A, Eisenberg M EClinicalMedicine. 2024; 75:102789.

PMID: 39246720 PMC: 11377134. DOI: 10.1016/j.eclinm.2024.102789.

Prevalence and factors associated with suboptimal blood pressure among ambulatory patients with diabetic kidney disease attending a tertiary hospital in Uganda.

Wamala D, Mutebi E, Kayima J Afr Health Sci. 2024; 23(2):490-498.

PMID: 38223567 PMC: 10782328. DOI: 10.4314/ahs.v23i2.57.

The denervation or activation of renal sympathetic nerve and renal blood flow.

Kharazmi F, Hosseini-Dastgerdi H, Pourshanazari A, Nematbakhsh M J Res Med Sci. 2023; 28:76.

PMID: 38152073 PMC: 10751519. DOI: 10.4103/jrms.jrms_216_23.

Adipose Tissue, Non-Communicable Diseases, and Physical Exercise: An Imperfect Triangle.

Monsalve F, Delgado-Lopez F, Fernandez-Tapia B, Gonzalez D Int J Mol Sci. 2023; 24(24).

PMID: 38138997 PMC: 10743187. DOI: 10.3390/ijms242417168.

References

Hering D, Mahfoud F, Walton A, Krum H, Lambert G, Lambert E . Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012; 23(7):1250-7. PMC: 3380649. DOI: 10.1681/ASN.2011111062. View

Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S . Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010; 55(3):619-26. DOI: 10.1161/HYPERTENSIONAHA.109.140665. View

Grassi G, Seravalle G, DellOro R, TURRI C, Bolla G, Mancia G . Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000; 36(4):538-42. DOI: 10.1161/01.hyp.36.4.538. View

Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E . Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006; 48(5):787-96. DOI: 10.1161/01.HYP.0000242642.42177.49. View

Lohmeier T, Iliescu R, Dwyer T, Irwin E, Cates A, Rossing M . Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010; 299(2):H402-9. PMC: 2930387. DOI: 10.1152/ajpheart.00372.2010. View

McCully B, Brooks V, Andresen M . Diet-induced obesity severely impairs myelinated aortic baroreceptor reflex responses. Am J Physiol Heart Circ Physiol. 2012; 302(10):H2083-91. PMC: 3362106. DOI: 10.1152/ajpheart.01200.2011. View

Lohmeier T, Warren S, Cunningham J . Sustained activation of the central baroreceptor pathway in obesity hypertension. Hypertension. 2003; 42(1):96-102. DOI: 10.1161/01.HYP.0000076092.10923.FD. View

Wanahita N, Messerli F, Bangalore S, Gami A, Somers V, Steinberg J . Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J. 2008; 155(2):310-5. DOI: 10.1016/j.ahj.2007.10.004. View

Lohmeier T, Iliescu R . Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation. J Appl Physiol (1985). 2012; 113(10):1652-8. PMC: 3524662. DOI: 10.1152/japplphysiol.00552.2012. View

10.

Esler M, Krum H, Sobotka P, Schlaich M, Schmieder R, Bohm M . Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376(9756):1903-9. DOI: 10.1016/S0140-6736(10)62039-9. View

11.

Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M . Interactions between leptin and the human sympathetic nervous system. Hypertension. 2003; 41(5):1072-9. DOI: 10.1161/01.HYP.0000066289.17754.49. View

12.

Pietrasik G, Goldenberg I, McNitt S, Moss A, Zareba W . Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007; 18(2):181-4. DOI: 10.1111/j.1540-8167.2006.00680.x. View

13.

Dibona G, Kopp U . Neural control of renal function. Physiol Rev. 1997; 77(1):75-197. DOI: 10.1152/physrev.1997.77.1.75. View

14.

Huber D, Schreihofer A . Attenuated baroreflex control of sympathetic nerve activity in obese Zucker rats by central mechanisms. J Physiol. 2010; 588(Pt 9):1515-25. PMC: 2876806. DOI: 10.1113/jphysiol.2009.186387. View

15.

Arone L, Mackintosh R, Rosenbaum M, Leibel R, Hirsch J . Autonomic nervous system activity in weight gain and weight loss. Am J Physiol. 1995; 269(1 Pt 2):R222-5. DOI: 10.1152/ajpregu.1995.269.1.R222. View

16.

Bisognano J, Bakris G, Nadim M, Sanchez L, Kroon A, Schafer J . Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011; 58(7):765-73. DOI: 10.1016/j.jacc.2011.06.008. View

17.

Hering D, Lambert E, Marusic P, Walton A, Krum H, Lambert G . Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2012; 61(2):457-64. DOI: 10.1161/HYPERTENSIONAHA.111.00194. View

18.

Tsuji H, Larson M, Venditti Jr F, Manders E, Evans J, Feldman C . Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996; 94(11):2850-5. DOI: 10.1161/01.cir.94.11.2850. View

19.

Schwartz P, De Ferrari G . Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev. 2010; 16(2):101-7. DOI: 10.1007/s10741-010-9179-1. View

20.

Witkowski A, Prejbisz A, Florczak E, KADziela J, Sliwinski P, Bielen P . Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011; 58(4):559-65. DOI: 10.1161/HYPERTENSIONAHA.111.173799. View